Envision ALR Announces Rapid Screening for Swine Flu Using Nanotechnology Based Plastic Electronics
News May 05, 2009
Envision ALR has announced that it is commercializing a new form of nanotechnology based infectious disease detection system with the capability to distinguish between different flu strains within seconds.
The technology has already been shown to be effective in lab tests and the company is now accelerating the commercialization program.
Envision ALR CEO Wassim Mourtada explained from Abu Dhabi "Global pandemics, or even the fear of them have a severe economic impact. With current disease identification technologies requiring blood samples to be shipped to a laboratory for testing, distinguishing between pandemic strains and common ones can take up to twenty-four hours. Our technology has the potential to reduce this to under a minute, requires either a pin prick of blood or a salvia sample and will deliver the result of the diagnoses on the spot."
The technology is based on printed electronics, making use of the properties of a number of nanoparticle based inks and the hand held device is portable for use in doctors’ surgeries, hospitals or airports.
The system works for both bacterial and viral pathogens, and tests performed by the Naval Research Lab in Washington DC using Staphylococcus Enterotoxin B showed a two order of magnitude improvement over the current 'Lab Golden Standard' test.
Nanoparticles show great promise as diagnostic tools and drug delivery agents. But until now, most nanoparticles had to be injected into the bloodstream because they weren’t absorbed well orally. Now, researchers have modified nanoparticles to improve their uptake in the gastrointestinal tract.